You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Clopidogrel was effective in patients who have MI with ST segment elevation receiving aspirin and fibrinolytic therapy

https://doi.org/10.1136/ebm.10.4.111

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179–89.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 Q In patients who have myocardial infarction (MI) with ST segment elevation and are receiving aspirin and standard fibrinolytic therapy, is the addition of clopidogrel beneficial?

    Clinical impact ratings Internal medicine ★★★★★★☆ Cardiology ★★★★★★★

    METHODS

    Embedded ImageDesign:

    randomised controlled trial (Clopidogrel as Adjunctive Reperfusion Therapy [CLARITY]–Thrombolysis in Myocardial Infarction [TIMI] 28 Study).

    Embedded ImageAllocation:

    concealed.*

    Embedded ImageBlinding:

    blinded (patients and healthcare providers).*

    Embedded ImageFollow up period:

    to the start of coronary angiography (median 3.5 d), or in patients not having angiography, to hospital discharge or day 8, whichever came first.

    Embedded ImageSetting:

    319 sites in 23 countries.

    Embedded ImagePatients:

    3491 patients who were 18–75 years (mean age 57 y, 80% men); presented within 12 hours after the onset of ischaemic discomfort at rest lasting >20 minutes; had ST segment elevation of ⩾0.1 mV in ⩾2 contiguous limb leads, ST segment elevation of ⩾0.2 mV in ⩾2 contiguous precordial …

    View Full Text

    Footnotes

    • ↵* See glossary.

    • For correspondence: Dr M S Sabatine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA. msabatinepartners.org

    • Sources of funding: Sanofi-Aventis and Bristol-Myers Squibb and National Heart, Lung and Blood Institute.